COVID-19 patients in critical conditions are hospitalized and treated with various protocols including antiviral drugs, which have been updated repeatedly. This study was aimed to analyze the demographics, costs, and outcomes of drug regimens in COVID-19 patients hospitalized in “Ali Asghar” hospital, affiliated with Shiraz University of Medical Sciences, from March 2019 to December 2020 as a retrospective study, approved by the ethics committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1399.1003) on Dec. 28, 2020. Using hospital information system (HIS) data, 2174 patients receiving favipiravir, remdesivir, interferon-β, and Kaletra^® were analyzed. Descriptive, univariate, and regression analyses were used. The costs and consequences of different drug regimens were significantly different (P value < 0.05); the highest and lowest costs belonged to remdesivir and Kaletra^®, respectively. The highest and lowest mean length of stay and mortality were related to remdesivir and favipiravir, respectively. Mortality did not differ significantly with various regimens. Length of stay was significantly shorter with favipiravir and Kaletra^® than interferon-β. Remdesivir had significantly the highest cost. Age presented a significantly positive relationship with mortality and length of stay. Besides, ICU admission significantly increased mortality, length of stay, and costs. Underlying diseases and low blood oxygen saturation contributed to mortality. COVID-19 correlation with age and underlying diseases is accordant with the published data. Given the highest costs and broad usage of remdesivir, besides controversies regarding its outcomes and side effects, a stricter evaluation of remdesivir benefits seems essential. Totally, COVID-19 therapeutic protocols should be selected carefully to optimize costs and outcomes.

处于危急状态的 COVID-19 患者住院并接受包括抗病毒药物在内的各种方案的治疗，这些方案已反复更新。本研究旨在分析 2019 年 3 月至 2020 年 12 月在设拉子医科大学附属“Ali Asghar”医院住院的 COVID-19 患者的人口统计、成本和药物治疗方案，作为一项回顾性研究，获得批准设拉子医科大学伦理委员会 (IR.SUMS.REC.1399.1003) 于 2020 年 12 月 28 日。使用医院信息系统 (HIS) 数据，2174 名接受法匹拉韦、瑞德西韦、干扰素-β和^{Kaletra®的患者}进行了分析。使用了描述性、单变量和回归分析。不同药物方案的成本和后果有显着差异（P值<0.05）；成本最高和最低的分别属于 remdesivir 和 Kaletra ^®。最高和最低的平均住院时间和死亡率分别与瑞德西韦和法匹拉韦有关。不同方案的死亡率没有显着差异。favipiravir 和 Kaletra ^®的住院时间明显短于干扰素-β. 瑞德西韦的成本明显最高。年龄与死亡率和住院时间呈显着正相关。此外，入住 ICU 显着增加了死亡率、住院时间和成本。基础疾病和低血氧饱和度导致死亡率。COVID-19 与年龄和基础疾病的相关性与已发表的数据一致。鉴于瑞德西韦的最高成本和广泛使用，除了关于其结果和副作用的争议外，对瑞德西韦的益处进行更严格的评估似乎至关重要。总体而言，应仔细选择 COVID-19 治疗方案以优化成本和结果。